Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer
Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer
复制标题
DOI：
10.1016/j.currproblcancer.2018.08.003
复制
发表时间：
2019-02-01
影响因子：
2.6
通讯作者：
Chen Dingding
中科院分区：
文献类型：
--
作者：
Abbas, Muhammad;Ahmed, Abrar;Chen Dingding
背景：癌胚抗原（CEA）、碳水化合物抗原（CA）-125、CA19-9和CA72-4是胃癌中经常发现的调节参数。目的：我们目前的研究重点是评估这些生物标志物对姑息化疗反应的同步性。方法：对216例接受一线顺铂化疗联合抗血管生成方案的胃癌患者进行回顾性研究。采集血样并进行生化和统计学分析。结果：216 名患者中有 78 名出现进展，中位无进展生存期 (PFS) 为 5 个月。对于血清 CEA，升高组和正常组的中位 PFS 分别为 4 个月和 7 个月（P = 0.01）。正常和升高的 CA19-9 和 CA72-4 的中位 PFS 分别为 6 个月和 4 个月 (P = 0.001)。在多变量Cox回归模型中，治疗前CEA、CA19-9水平升高和远处转移是与进展风险增加相关的独立因素（分别为P = 0.021、P = 0.000、P = 0.006）。 结论： 总之，治疗前CEA和CA19-9水平升高与进展风险高和预后较差相关。此外，额外的抗血管生成疗法在降低姑息化疗后的癌症生物标志物水平方面更有效，这可能与治疗成功相关。 (C) 2018 Elsevier Inc. 保留所有权利。
Background: Carcinoembryonic antigen (CEA), carbohydrate antigen (CA)-125, CA19-9, and CA72-4 are often found modulated parameters in gastric cancer.Objective: Our present study is focused to evaluate the synchronization of these biomarkers in response to palliative chemotherapy.Method: A retrospective study was conducted on 216 gastric cancer patients undergoing first-line cisplatin chemotherapy along with antiangiogenic regimen. Blood samples were taken and analyzed biochemically and statistically.Results: Progression occurred in 78 of 216 patients and the median progression-free survival (PFS) was 5 months. For serum CEA, the median PFS was 4 versus 7 months for elevated and normal groups respectively (P = 0.01). The median PFS for normal and elevated CA19-9 and CA72-4 was 6 vs 4 months respectively (P = 0.001). In the multivariate Cox regression model, elevated pretreatment level of CEA, CA19-9, and distant metastases were independent factors associated with increased risk of progression (P = 0.021, P = 0.000, P = 0.006, respectively).Conclusions: Conclusively, elevated pretreatment level of CEA and CA19-9 is correlated with high risk of progression and worse prognosis. Moreover, an additional antiangiogenic therapy is more effective in decreasing cancer biomarker level after palliative chemotherapy that may be correlated with therapeutic triumph. (C) 2018 Elsevier Inc. All rights reserved.